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Abstract
A stage-associated gene expression signature of coordinately expressed genes, including the transcription factor Slug
(SNAI2) and other epithelial-mesenchymal transition (EMT) markers has been found present in samples from publicly
available gene expression datasets in multiple cancer types, including nonepithelial cancers. The expression levels of the co-
expressed genes vary in a continuous and coordinate manner across the samples, ranging from absence of expression to
strong co-expression of all genes. These data suggest that tumor cells may pass through an EMT-like process of
mesenchymal transition to varying degrees. Here we show that, in glioblastoma multiforme (GBM), this signature is
associated with time to recurrence following initial treatment. By analyzing data from The Cancer Genome Atlas (TCGA), we
found that GBM patients who responded to therapy and had long time to recurrence had low levels of the signature in their
tumor samples (P=3 610
27). We also found that the signature is strongly correlated in gliomas with the putative stem cell
marker CD44, and is highly enriched among the differentially expressed genes in glioblastomas vs. lower grade gliomas. Our
results suggest that long delay before tumor recurrence is associated with absence of the mesenchymal transition
signature, raising the possibility that inhibiting this transition might improve the durability of therapy in glioma patients.
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Introduction
A multi-cancer stage-associated gene expression signature has
recently been identified [1], consisting of a set of genes that are
coordinately overexpressed only in samples of cancer that have
exceeded a particular stage specific to each cancer type. Table 1
contains a list of the 64 genes corresponding to the top 100 probe
sets (as presented in [1]) of the signature. The signature contains
numerous epithelial-mesenchymal transition (EMT) markers
[2,3,4], such as the EMT-inducing transcription factor Slug
(SNAI2), as well as COL5A2, FAP, POSTN, COL1A2, COL3A1,
FBN1, TNFAIP6, MMP2, GREM1, BGN, CDH11, SPOCK1,
DCN, COPZ2, THY1, PCOLCE, PRRX1, PDGFRB, SPARC,
INHBA, COL6A2, FN1, ACTA2. However, the signature is also
present even in some nonepithelial cancers, such as neuroblastoma
and Ewing’s sarcoma. In each dataset, the expression level of the
co-expressed genes varies in a continuous manner across the
samples. In a recent experiment we also confirmed that most of the
genes of the signature, including a-SMA, are expressed in some
xenografted human cancer cells themselves in vivo, but not in the
host mouse cells [5]. These results indicate that cancer cells can
pass through a mesenchymal transition process to varying degrees
ranging from total lack of expression to strong co-expression of the
genes of the signature, and therefore the corresponding underlying
pathways are activated within the cancer cells, in conjunction with
other pathways in the tumor microenvironment providing
contextual interactions.
The average expression level of these 64 genes can be thought of
as the expression level of a metagene representing the signature, to
which we refer as the ‘‘mesenchymal transition metagene.’’ We
hypothesized that this value is associated with clinical data in
glioblastoma multiforme (GBM) for which there is rich such data
available at The Cancer Genome Atlas (TCGA). We found that
there was indeed strong association of the metagene with the
phenotype ‘‘Days to Tumor Recurrence,’’ defined as the time
period from initial treatment until the date of the diagnosis or
recognition of the presence and nature of the return of signs and
symptoms of cancer following a period of improvement. Patients
who did not experience improvement after therapy have a ‘‘null’’
entry in the corresponding field.
Methods
For statistical analysis we used the rank sum of the patients with
long time to recurrence after ranking the patients in terms of the
mesenchymal transition metagene. To evaluate the statistical
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34705significance, we calculated the P value from its definition using
empirical distribution function. In addition, we performed Cox
regression between days to tumor recurrence and the expression
level of the signature.
We also performed multivariate Cox regression on days to
tumor recurrence, using both the expression values of the
mesenchymal transition metagene and the four glioblastoma
subtypes as covariates.
Results
Figure 1 shows a scatter plot in which each of the 99 samples for
which the ‘‘Days to Tumor Recurrence’’ phenotype has a non-null
entry is represented by a dot indicating the expression level of the
mesenchymal transition metagene and the number of days to
tumor recurrence. The figure reveals that, within the group of
patients who experienced improvement after therapy, the eight
patients whose tumors recurred more than three years following
therapy have very low values of the expression of the metagene.
Figure 2 shows a heat map of the 64 genes, where the samples are
ranked in terms of the expression of the metagene and the eight
patients for which time to recurrence was more than three years
are highlighted in green. The rank sum for these eight patients is
1+2+6+7+9+11+16+18=70. The rank sum is particularly well
suited as a measure of this particular observed aspect of the
association of the ‘‘Days to Tumor Recurrence’’ phenotype with
the expression of a gene, in which absence of gene expression is
required for exceptionally long time to recurrence. The probability
of the rank sum being #70 due to pure chance is estimated as the
relative frequency of such occurrences after randomly permuting
the phenotypes ten million times and recalculating the rank sum,
concluding that P=3 610
27, which is also the probability of
finding that the sum of eight randomly picked distinct numbers
between 1 and 99 is less than or equal to 70.
We also separated the entire set of 545 tumor samples into two
groups of equal size, containing high vs. low levels of the
mesenchymal transition metagene. Within the 99 samples
containing a ‘‘Days to Tumor Recurrence’’ field, there were 48
Table 1. Genes comprising the Slug-based EMT signature.
Rank Gene Rank Gene
1 COL11A1 33 LOXL2
2 THBS2 34 COL6A3
3 COL10A1 35 MXRA5
4 COL5A2 36 MFAP5
5 INHBA 37 NUAK1
6 LRRC15 38 RAB31
7 COL5A1 39 TIMP3
8 VCAN 40 CRISPLD2
9 FAP 41 ITGBL1
10 COL1A1 42 CDH11
11 MMP11 43 TMEM158
12 POSTN 44 SPOCK1
13 COL1A2 45 SFRP4
14 ADAM12 46 SERPINF1
15 COL3A1 47 DCN
16 LOX 48 C7orf10
17 FN1 49 COPZ2
18 AEBP1 50 NOX4
19 SULF1 51 EDNRA
20 FBN1 52 ACTA2
21 ASPN 53 PDGFRB
22 SPARC 54 RCN3
23 CTSK 55 SNAI2
24 TNFAIP6 56 C1QTNF3
25 HNT 57 COMP
26 EPYC 58 LGALS1
27 MMP2 59 THY1
28 PLAU 60 PCOLCE
29 GREM1 61 COL6A2
30 BGN 62 GLT8D2
31 OLFML2B 63 NID2
32 LUM 64 PRRX1
doi:10.1371/journal.pone.0034705.t001
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34705Figure 1. Scatter plot for Days to Tumor Recurrence vs. expression of the mesenchymal transition metagene. Each dot in the scatter
plot represents one of the 99 patients for which the ‘‘Days to Tumor Recurrence’’ phenotype has a non-null entry. The horizontal axis measures the
average of the RMA-normalized expression levels of the 64 genes shown in Table 1. The vertical axis measures the days to tumor recurrence and the
horizontal dotted line is drawn at the 3 year cutoff point.
doi:10.1371/journal.pone.0034705.g001
Figure 2. Heat map of the components of the mesenchymal transition metagene in glioblastoma. The 99 samples are ranked in terms of
the average expression level of the genes shown in Table 1. The eight patients for which time to recurrence was more than three years are
highlighted in green at the 1
st,2
nd,6
th,7
th,9
th,1 1
th,1 6
th, and 18
th position, resulting in the rank sum of 70.
doi:10.1371/journal.pone.0034705.g002
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regression between days to tumor recurrence and the expression
level of the signature. Figure 3 contains the corresponding Kaplan-
Meier survival curves resulting in a clearly seen association with
statistical significance of P=0.0054 using a chi-squared test.
We then used the rank sum metric to identify which, among the
individual 64 genes of Table 1 defining the metagene have the best
score, expecting that some of them would have rank sum lower
than 70. Remarkably, the best scoring gene was COL5A1 with
rank sum equal to 78 followed by COL6A2 with rank sum equal to
82. In other words, the score of the metagene is significantly better
than that of any of its individual component genes. Even more
strikingly, after doing exhaustive search among all 12,042 genes,
the top ranked gene (EFEMP2) had rank sum equal to 75, still
worse than that (70) of the metagene. These results suggest that the
signature identified in [1] comprises a synergistic collection of
genes corresponding to a biological mechanism of mesenchymal
transition, which, when absent, is associated with increased time
period to tumor recurrence in GBM.
Table 2 shows a listing of the top 30 individual genes in terms of
their rank sum for the ‘‘Days to Tumor Recurrence’’ phenotype.
Nine out of these 30 genes, highlighted in Table 2, are among the
64 genes of Table 1, demonstrating the strong enrichment
(P=3 610
214) of EMT markers in this unbiased collection of
genes associated with the phenotype.
While all cases in the TCGA dataset have been diagnosed as
glioblastoma, the delayed recurrence in these eight cases is more a
characteristic of lower grade gliomas. Therefore, we investigated
whether lower grade gliomas are also characterized by lower levels
of the signature by analyzing the NCI Repository for Molecular
Brain Neoplasia Data (Rembrandt) dataset, which included gene
expression from both glioblastoma as well as various types of lower
grade gliomas. Table 3 demonstrates that, indeed, there is strong
enrichment (seven of the 64 genes in Table 1 are among the top-
ranked 30 differentially expressed genes, P=10
213). Furthermore,
we found strong correlation between the expression levels of the
metagene and the cancer stem cell marker CD44 (P=5 610
256
based on fitting Pearson correlation to t-distribution). Figure 4
shows the corresponding scatter plot. Recent studies have shown
that high levels of CD44 are expressed in cancer stem cells isolated
from several different types of tumors [6], although this concept is
still in evolution, and CD44 is also expressed in a variety of other
cell types. CD44 has been found in a cell population enriched for
glioma stem cells [7]. It is also widely expressed in glioblastoma,
and increased levels are associated with glioma progression and
resistance to therapy [8].
Analysis of gene expression data has resulted in classification
into various subtypes of glioblastomas [9,10], also present in lower
grade gliomas [11], with distinct features, each of which is
characterized by the presence of particular genes. Interestingly,
CD44 was found enriched in the mesenchymal subtypes in all
these cases. The feature of our current results, however, is that the
mesenchymal transition signature used in this paper reflects a
biological process applicable to multiple cancer types, as it was
derived by analyzing its presence in many different cancers [1], as
opposed to using classification methods on glioma samples alone to
Figure 3. Kaplan-Meier curves comparing samples with high vs. low levels of the mesenchymal transition metagene. The 545 tumor
samples were partitioned into two groups of equal size depending on their levels of the mesenchymal transition metagene. Shown are the Kaplan-
Meier curves for the corresponding samples with entries in the ‘‘Days to Tumor Recurrence’’ field.
doi:10.1371/journal.pone.0034705.g003
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is found in the absence, rather than the presence, of the signature.
To confirm that the observed association with the ‘‘Days to
Tumor Recurrence’’ phenotype is more related to the presence of
the mesenchymal transition signature, rather than to the
classification into a mesenchymal subtype, we performed multi-
variate Cox regression on days to tumor recurrence, using both the
expression values of the mesenchymal transition metagene and the
four subtypes [9] as covariates. The subtype variable is a
categorical variable with four types (Mesenchymal, Classical,
Neural and Proneural). To infer the samples whose subtypes were
not given in the original paper, we performed a ten-nearest
neighbor imputation based on the signature genes of the four
subtypes as given in [9]. The result shows that the mesenchymal
transition metagene expression variable is the only significant
covariate (with P=0.049), while the rest of the categorical
variables did not pass the significance level of 0.05 (the minimum
was 0.160 for the Mesenchymal subtype), demonstrating that the
‘‘Days to Tumor Recurrence’’ phenotype is most significantly
associated with the mesenchymal transition signature. The results
of Cox regression are shown in Table 4.
To further compare directly the mesenchymal transition
signature with that of the Mesenchymal subtype of [9], we created
a metagene for the latter so that we can evaluate its association
with the ‘‘Days to Tumor Recurrence’’ phenotype as measured by
the rank sum. This was created using the gene list as described in
the supplementary information of the paper, available at http://
tcga-data.nci.nih.gov/docs/publications/gbm_exp. Specifically, in
the associated data file containing the expression values and
subtype calls for the Core TCGA samples using the unified scaled
data, there are 216 genes labeled as mesenchymal. These genes
were ranked in terms of their power to represent the mesenchymal
phenotype, as determined by the differences between each gene’s
mesenchymal centroid component and the centroid component of
the remaining subtypes, which can also be regarded as the log-fold
change between the gene’s mean value in the mesenchymal
subtype and the gene’s overall mean [12] (as quoted in the data file
containing the ClaNC840 gene list and centroids). Based on that
ranking, we selected the top 64, so that the sizes of the two
Table 2. Top genes in terms of the rank sum for the ‘‘Days to
Tumor Recurrence’’ phenotype.
Genes Rank sum
EFEMP2 75
CD248 78
COL5A1 78
IL7R 78
MYH9 81
COL6A2 82
FLNC 82
AKAP12 87
TREM1 87
COL1A2 88
PSCDBP 88
S100A8 91
CLEC2B 92
GLIPR1 98
COL6A3 99
THBD 99
CALD1 102
CD163 102
EFEMP1 102
ENPEP 103
PCOLCE 103
TMEM5 103
SDCBP 104
COL1A1 105
LUM 105
TNC 106
VNN1 106
CARS 107
FN1 107
COL3A1 108
doi:10.1371/journal.pone.0034705.t002
Table 3. Top differentially expressed gene in glioblastomas
vs. lower grade gliomas.
Probe Set ID Gene Symbol Fold Change
209395_at CHI3L1 10.36
202718_at IGFBP2 6.07
210809_s_at POSTN 5.77
201666_at TIMP1 5.70
1556499_s_at COL1A1 5.69
215076_s_at COL3A1 5.59
202404_s_at COL1A2 5.17
206157_at PTX3 4.90
201012_at ANXA1 4.87
202237_at NNMT 4.82
211527_x_at VEGFA 4.73
221898_at PDPN 4.65
202912_at ADM 4.65
215446_s_at LOX 4.43
202345_s_at FABP5 4.41
226517_at BCAT1 4.30
203729_at EMP3 4.14
202018_s_at LTF 4.05
227697_at SOCS3 3.96
211981_at COL4A1 3.64
209156_s_at COL6A2 3.62
201505_at LAMB1 3.59
226237_at 226237_at 3.59
236028_at IBSP 3.57
201744_s_at LUM 3.53
225681_at CTHRC1 3.52
203645_s_at CD163 3.51
211964_at COL4A2 3.49
201110_s_at THBS1 3.44
208949_s_at LGALS3 3.42
doi:10.1371/journal.pone.0034705.t003
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sum was 142 (it would have been 151 if using all 216 genes). This
should be compared with the corresponding value of 70 of the
mesenchymal transition metagene and with the other entries of
individual genes in Table 2. These results further confirm that the
observed association with days to tumor recurrence is due to the
multi-cancer mesenchymal transition signature, which has the
remarkable property that the corresponding metagene has lower
rank sum than any individual gene.
Discussion
Because gliomas are not epithelial cancers, and the signature
has also been found in other nonepithelial cancers, such as
neuroblastoma and Ewing’s sarcoma, the signature represents a
more general biological process of mesenchymal transition,
applicable to all solid cancers that we tried. Indeed, when the
set of genes of Table 1 are the input for Gene Set Enrichment
Analysis (GSEA) [13] against the Molecular Signatures Database
(MSigDB), there are many results with P value exactly equal to
‘‘zero,’’ corresponding to genes expressed in higher-stage samples
Figure 4. Scatter plot for the expression levels of CD44 vs. the mesenchymal transition metagene. Each dot in the scatter plot represents
a glioma sample from the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt) dataset. Dots are color coded red for glioblastomas and
blue for lower grade gliomas. Expression levels are RNA normalized.
doi:10.1371/journal.pone.0034705.g004
Table 4. Multivariate Cox regression using GBM subtypes as covariates.
Coefficient SE(Coef) Hazard ratio (95% CI) P value
Mesenchymal transition metagene 0.307 0.156 1.359 (1.001–1.844) 0.049
Subtype*
Overall 1.000
Mesenchymal 0.284 0.203 1.328 (0.892–1.977) 0.160
Classical 20.141 0.175 0.868 (0.617–1.223) 0.419
Neural 0.080 0.255 1.083 (0.657–1.785) 0.750
Proneural 20.222 0.203 0.801 (0.537–1.193) 0.270
Likelihood ratio test=12.3, degrees of freedom=4, P value=0.0153.
*The table shows all four linear contrasts between individual subtype mean log-hazard ratios and overall mean log-hazard ratio. In practice there are three contrasts in
each Cox regression regardless of which contrast is chosen as the noncoding group. We used two separate Cox regressions to produce the results in the table.
doi:10.1371/journal.pone.0034705.t004
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urothelial, lymphomas, etc. Such cancer types had not participated
in any way whatsoever in the derivation of the signature. This
remarkable validation of the signature by pointing to all kinds of
cancer types in MSigDB suggests that the signature may reflect a
universal biological mechanism of mesenchymal transition present
in the invasive stage of all solid cancers including glioblastoma.
Analysis of related datasets suggests that there are multiple affected
pathways comprising a particularly complex biological mechanism
that appears to reactivate embryonic developmental programs.
Indeed, when analyzing the 64-gene signature against MSigDB
Gene Ontology biological process datasets, the top five results
were all related to development (skeletal, organ, multicellular
organismal, system, anatomical structure). The prominent GO
cellular component was extracellular matrix, and the prominent
GO molecular function was collagen binding.
It has recently been suggested that ‘‘stemness’’ in tumor cells
(characterized by the ability to both self-renew as well as generate
differentiated descendants) may be intimately interconnected with
passing through an EMT. For example, EMT in some models was
found to generate cells with properties of stem cells
[14,15,16,17,18]. Notably, it has been shown that stem-like cells
isolated from human breast cancer co-express high levels of CD44
and high levels of mesenchymal markers, including Slug [14].
Furthermore, inducing EMT in immortalized human mammary
epithelial cells leads to high levels of CD44 expression in the
mesenchymal-like cells [14]. Drug resistance has also been linked
to the presence of cancer stem cells [16,18,19,20], supporting the
notion that cancer stem cells may be responsible for recurrence
after therapeutic intervention. Therefore, and given the strong
correlation of the mesenchymal transition signature with CD44,
one possible explanation for the absence of the mesenchymal
transition signature in patients with exceptionally long time to
recurrence may be due to a corresponding lack of stemness in the
cancer cells of these patients making it more unlikely for the cancer
to recur following treatment. An alternative explanation for the
observed association may be provided by the transformation
towards a more mesenchymal phenotype [21].
Although there are several EMT-inducing transcription factors
[22], some of which are also found occasionally upregulated in the
mesenchymal transition signature characterized by the genes in
Table 1, Slug is the only one found consistently upregulated. It was
also the only such transcription factor upregulated in our
experimental xenografts [5]. Slug has also recently been found
to be associated with invasiveness in glioma [23], consistent with
the results presented here. Furthermore, when we ranked all genes
in terms of their correlation (using the measure of mutual
information [24]) of their expression with that of Slug in the 99
samples that we analyzed here, we found that, remarkably, the top
eight entries (COL6A3, COL3A1, LUM, COL5A1, COL1A2,
COL6A2, COL1A1, PCOLCE) were all genes included in both
Tables 1 as well as Table 2, further supporting the hypothesis that
Slug might be a master regulator of the biological mechanism
responsible for the signature. It was recently found [25], however,
that induced overexpression of the transcription factor Twist in
glioblastoma leads to increased invasiveness and expression of
several of the genes in Table 1, including Slug, suggesting that
Twist may play a causative role for the mesenchymal transition in
glioblastoma.
The same signature was also found to be predictive of
neoadjuvant therapy in breast cancer - see, e.g. additional file 6
of [1], in which 7 of 8 samples in the cluster on the left side of the
heat map (with low levels of the signature) had good response to
therapy, while 12 out of 14 samples in the second cluster (with high
levels of the signature) were resistant.
The observations that (a) all GBM patients with exceptionally
long time to recurrence had extremely low levels of the
mesenchymal transition gene signature, and (b) the mesenchymal
transition signature is strongly enriched among the genes under-
expressed in lower grade gliomas as compared to glioblastomas,
suggest that targeting the underlying biological mechanism might
supply a novel approach for adjuvant treatment of gliomas.
Further, the ability to precisely identify components of the gene
signature provides unique opportunities for identifying potential
targets for such treatment.
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